Avalon GloboCare Corp

Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and the provision of healthcare services. It operates through the following segments: Real Property Operating, Medical Related Consulting Services, and Development Services & Sales of Developed Products. It offers regenerative medicine, cell-based immunotherapy, exosome technology, and rehabilitation medicine through Avalon Cell and Avalon Rehab platforms. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avalon GloboCare Corp. is a clinical-stage biotechnology company, which engages in the development of immune effector cell therapy and laboratory services. It operates through the Real Property Operating and Medical Related Consulting Services segments. The Real Property Operating segment includes property management fees, property insurance, real estate taxes, depreciation, repairs and maintenance fees, utilities and other expenses related to rental properties. The Medical Related Consulting segment relates to labor and related benefits, travel expenses, and related to consulting services. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.

Company to Begin Trading under New Symbol “ALBT” on November 10, 2022

Avalon GloboCare Announces NASDAQ Ticker Symbol Change from “AVCO” to “ALBT”

Company to acquire a majority interest in Laboratory Services MSO, LLC,  a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests completed since inception

Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 Million

bioAffinity Technologies Inc

Ocular Therapeutix

What happened in the stock market today and Penny stocks to watch this week. The post Stock Market Today: What Happened & 3 Penny Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Stock Market Today: What Happened & 3 Penny Stocks To Watch Now

Avalon GloboCare Corp (NASDAQ:AVCO) has received a notice of allowance from the US Patent and Trademark Office (USPTO) related to its QTY fusion water-soluble receptor protein platform. The company's QTY code is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their potential use in many clinical applications, including drug development, the company said.

Avalon GloboCare gets notice of allowance from US patent office for QTY fusion platform

Jointly with MIT, the Company also Submitted a New U.S. Patent Application for QTY Glucose Transporters Jointly with MIT, the Company also Submitted a New U.S. Patent Application for QTY Glucose Transporters

Avalon GloboCare Receives Allowance for Joint U.S. Patent

Avalon GloboCare Corp (NASDAQ:AVCO) said that an article featuring its QTY protein code technology was published in Chemical Reviews, the official journal of the American Chemical Society.  The publication, titled “Protein Design: From the Aspect of Water Solubility and Stability,” discusses the innovative QTY protein design code, which Avalon co-designed, as a novel platform to generate water-soluble proteins for a wide spectrum of biomedical applications.

Avalon GloboCare says its co-developed QTY code protein code technology featured in Chemical Reviews

Findings support utility of QTY protein code as a novel platform to generate water-soluble proteins for wide spectrum of biomedical applications

Avalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical Society

Avalon GloboCare Corp (NASDAQ:AVCO) announced a new study incorporating artificial intelligence (AI)-enhanced protein design technology that could accelerate development of therapeutic monoclonal antibodies to treat cancer. Developed by Avalon, the QTY code technology is a protein-design platform that can turn water-insoluble transmembrane receptor proteins into water-soluble proteins for use in clinical applications, including drug development.

Avalon GloboCare reveals new study using AI-powered protein design technology targeting glucose transporter against cancer

FREEHOLD, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new study applying artificial intelligence (AI) enhanced protein design “QTY Code” technology. The method is expected to accelerate development of therapeutic monoclonal antibodies to treat cancer.

Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer

FREEHOLD, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer, of Avalon GloboCare, will be presenting at the Jefferies 2022 Healthcare Conference which is being held on June 8–10, 2022 in New York City.

Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference

Avalon GloboCare Corp (NASDAQ:AVCO) has signed a memorandum of understanding with Lu Daopei Hematology Institute (LDHI) to co-develop precision companion diagnostics for chimeric antigen receptor (CAR)-T cell therapies, the company announced. LDHI is a hematology research institute based in Beijing developing precision diagnostics based on personalized genomic, proteomic, transcriptomic and metabolomic platforms.

Avalon GloboCare to team up with Lu Daopei Hematology Institute to develop companion diagnostics for CAR-T cancer treatments

Avalon GloboCare Corp (NASDAQ:AVCO) has revealed that is has filed 16 patent applications related to novel cellular therapies and related technologies as the company moves towards clinical trials. The company said the patents were filed with US Patent and Trademark Office, the China National Trademark Office, and under the Patent Cooperation Treaty covering 36 countries.

Avalon GloboCare files 16 patent applications related to cellular therapies as company moves towards clinical trials

Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies. Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors.

Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform

Avalon GloboCare Corp (NASDAQ:AVCO) said it is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) cell therapies. Natural killer (NK) cells constitute an important component of the immune system.

Avalon GloboCare expands its cellular immuno-oncology program with addition of Chimeric Antigen Receptor-Natural Killer cell therapies

FREEHOLD, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, announced today that the Company is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies.

Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies

Avalon GloboCare Corp (NASDAQ:AVCO) told investors it was 'well positioned' to execute on its growth strategy this year as the company highlighted it had partnered with world-renowned research centers and universities. In a year-end update, the clinical stage, cell therapy company noted its new collaboration with the University of Pittsburgh Medical Center (UPMC) to develop new cancer immunotherapy approaches and streamline manufacturing processes.

Avalon GloboCare well poised for growth this year; intended SenlangBio acquisition terminated

Company continues to expand and accelerate its R&D strategies for high-impact translational and clinical programs in the US and Europe

Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs

Avalon's Chairman converts $3.0 million of debt into common stock at $1.25 per share showing continued confidence and support of the business Avalon's Chairman converts $3.0 million of debt into common stock at $1.25 per share showing continued confidence and support of the business

Avalon GloboCare's Chairman Converts Debt into Common Stock at 45% Premium to Market

Avalon GloboCare Corp (NASDAQ:AVCO) announced that it has further advanced its research to accurately predict the 3-dimensional structures of protein receptors for potential use as cellular therapy targets, in partnership with the Massachusetts Institute of Technology (MIT). The Toronto-based company collaborated with the institute to combine its artificial intelligence (AI)-enhanced protein design ‘QTY Code' technology with Google's AlphaFold2, a DeepMind AI program developed to predict 3D protein structures of previously difficult to work with drug targets.

Avalon GloboCare advances its AI-enhanced protein design technology for cellular therapy development in collaboration with MIT

FREEHOLD, N.J., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced further advancement of the Company's sponsored research and licensing agreement with the Massachusetts Institute of Technology (MIT). Avalon and MIT have combined their artificial intelligence (AI)-enhanced protein design “QTY Code” technology with Google's AlphaFold2, a DeepMind AI program developed to predict 3-dimensional (3D) protein structures of previously difficult to work with drug targets. This new system is designed to accelerate and advance Avalon's capabilities in developing novel targets for immuno-oncology and cellular medicine.

Avalon GloboCare Advances AI-Enhanced Protein Design Technology for Cellular Therapy Development

Avalon GloboCare Corp. has successfully co-developed a novel platform of S-layer coated emulsome technology (SLET) for next-generation drug delivery and cellular immunotherapy.

Avalon GloboCare successfully co-develops novel platform of S-layer coated emulsome technology for next-generation drug delivery and cellular immunotherapy

FREEHOLD, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced it has successfully co-developed a novel platform of S-layer coated emulsome technology (SLET) for next-generation drug delivery and cellular immunotherapy, together with Professor Uwe Sleytr and the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria.

Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy

Avalon GloboCare Corp. has announced the co-development of a novel, cell-free, in-silico system to facilitate its drug development efforts.

Avalon GloboCare announces co-development of in-silico system to expand its ability to design and produce novel cell membrane proteins

Image Provided by Pixabay Cytokine storm has made frequent appearances in the news lately as a life-threatening complication in patients suffering from COVID-19. The condition is an inflammatory syndrome triggered by hyperactivation of immune cells that can significantly impact the patient's chances of making a full recovery or surviving the infection at all.

Avalon GloboCare's Advanced Filtration Tech Could Help Stop Life-Threatening Cytokine Storm in COVID-19 Patients

FREEHOLD, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced co-development of a novel, cell-free, in-silico system to facilitate the Company's drug development efforts, together with the Institute for Synthetic Bioarchitectures at the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria. A study of the new technology was featured in the September 2021 issue of Membranes, an international, peer-reviewed journal.

Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for Cancer and Immune-Related Diseases

News for Avalon GloboCare Corp Stock (AVCO)